Shares of Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) have received an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $53.13.
A number of research firms have issued reports on ARVN. Piper Sandler reduced their target price on shares of Arvinas from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, October 23rd. Barclays reduced their target price on shares of Arvinas from $39.00 to $26.00 and set an “overweight” rating on the stock in a report on Tuesday, October 24th. The Goldman Sachs Group began coverage on shares of Arvinas in a report on Thursday, February 1st. They set a “buy” rating and a $70.00 target price on the stock. Guggenheim upgraded shares of Arvinas from a “neutral” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Monday, November 20th. Finally, Wells Fargo & Company upgraded shares of Arvinas from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $25.00 to $63.00 in a report on Tuesday, December 19th.
Institutional Investors Weigh In On Arvinas
Arvinas Stock Performance
NASDAQ:ARVN opened at $51.18 on Tuesday. The stock has a market capitalization of $2.82 billion, a P/E ratio of -9.25 and a beta of 1.96. The company has a 50 day moving average price of $39.24 and a 200 day moving average price of $27.87. Arvinas has a fifty-two week low of $13.57 and a fifty-two week high of $52.05.
Arvinas Company Profile
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
- Five stocks we like better than Arvinas
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 attractive stocks that insiders are buying
- Why Consider Investing in Nanotechnology Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Bank Stocks – Best Bank Stocks to Invest In
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.